Recent News

• 05.28.2025 - SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
• 05.15.2025 - SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.15.2025 - SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 04.08.2025 - SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
• 03.12.2025 - SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
• 03.12.2025 - SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
• 12.18.2024 - SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
• 12.18.2024 - SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

Recent Filings

• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.30.2025 - DEF 14A Other definitive proxy statements
• 04.30.2025 - ARS Annual Report to Security Holders
• 04.30.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.12.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.27.2025 - 4 Statement of changes in beneficial ownership of securities